Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Public Health Agency of Canada, Ottawa, Ontario, Canada.
Paediatr Perinat Epidemiol. 2023 Jul;37(5):473-484. doi: 10.1111/ppe.12963. Epub 2023 Mar 20.
Acetaminophen is a frequently used analgesic for pain and fever. There have been reports of adverse neurodevelopmental outcomes associated with in utero acetaminophen exposure. However, it is unclear whether this association is related directly to acetaminophen use, or the reasons for use.
To summarise the literature on the association between in utero acetaminophen exposure and child neurodevelopmental outcomes, and assess the extent to which the association is due to confounding by indication.
OVID for Medline, Embase, and PsycINFO, and EBSCO for CINAHL, from inception to August 18, 2022.
We searched for peer-reviewed, English-language studies on in utero acetaminophen exposure and child neurodevelopmental outcomes. Data were extracted using a standardised form created a priori, and quality was assessed using the Systematic Assessment of Quality in Observational Research.
We generated pooled risk ratios (RR) for outcomes examined by ≥3 studies using random-effects models; outcomes that could not be meta-analysed were narratively summarised following Synthesis Without Meta-Analysis guidelines.
Twenty-two studies including 23 cohorts were eligible (n = 367,775 total participants; median: 51.7% with acetaminophen exposure). Studies were primarily prospective cohort studies from Europe and the US, with attention deficit/hyperactivity disorder (ADHD) being the most common outcome. Quality assessments resulted in 13.6% of studies being classified as high, 59.1% as medium, 22.7% as low, and 4.5% as very low quality. In utero acetaminophen exposure was associated with an elevated risk of ADHD (unadjusted pooled RR 1.32, 95% confidence interval [CI] 1.20, 1.44; I = 47%, n = 7 studies), with little difference after adjusting for confounders, including indications for acetaminophen use (adjusted pooled RR 1.34, 95% CI 1.15, 1.55; I = 50%, n = 4 studies).
Confounding by indication did not explain the association between in utero acetaminophen exposure and child ADHD. Further, high-quality research is needed on this and other neurodevelopmental outcomes.
对乙酰氨基酚是一种常用于缓解疼痛和发热的止痛药物。有报道称,在子宫内接触对乙酰氨基酚与不良神经发育结局有关。然而,目前尚不清楚这种关联是否与对乙酰氨基酚的使用直接相关,或者与使用的原因有关。
总结关于子宫内接触对乙酰氨基酚与儿童神经发育结局之间关联的文献,并评估该关联在多大程度上受到指示性混杂的影响。
2022 年 8 月 18 日以前,通过 OVID 对 Medline、Embase 和 PsycINFO 以及 EBSCO 对 CINAHL 进行了文献检索。
我们检索了关于子宫内接触对乙酰氨基酚与儿童神经发育结局的同行评议的英文研究。使用预先制定的标准化表格提取数据,并使用系统评价方法评估研究质量。
我们使用随机效应模型对至少有 3 项研究检查的结局生成汇总风险比(RR);对于无法进行荟萃分析的结局,我们根据“无荟萃分析的综合分析指南”进行了叙述性总结。
纳入了 22 项研究,共包含 23 个队列(n=367775 名参与者;中位数:51.7%接触过对乙酰氨基酚)。这些研究主要是来自欧洲和美国的前瞻性队列研究,其中注意力缺陷/多动障碍(ADHD)是最常见的结局。质量评估结果显示,13.6%的研究被归类为高质量,59.1%为中质量,22.7%为低质量,4.5%为极低质量。子宫内接触对乙酰氨基酚与 ADHD 风险升高相关(未经调整的汇总 RR 1.32,95%置信区间 [CI] 1.20,1.44;I 2=47%,n=7 项研究),在调整了包括对乙酰氨基酚使用指征在内的混杂因素后,差异仍有统计学意义(调整后的汇总 RR 1.34,95% CI 1.15,1.55;I 2=50%,n=4 项研究)。
指示性混杂并不能解释子宫内接触对乙酰氨基酚与儿童 ADHD 之间的关联。此外,还需要关于这一关联和其他神经发育结局的高质量研究。